Mi SciELO
Servicios Personalizados
Articulo
Indicadores
- Citado por SciELO
Links relacionados
- Similares en SciELO
Compartir
Revista Cubana de Medicina
versión On-line ISSN 1561-302X
Resumen
RODRIGUEZ, José Hernández. Semaglutide in the Treatment of Diabesity Individuals. Rev. Cuban de Med [online]. 2023, vol.62, n.1 Epub 01-Mar-2023. ISSN 1561-302X.
Introduction:
Semaglutide is a drug that contributes to the release of insulin from the pancreas and suppresses appetite, which makes it an important candidate for treating diabesity.
Objective:
To describe the role of semaglutide in the treatment of diabesity individuals.
Methods:
The necessary information to write this article was obtained in the 2022 two-month period January-February. The keywords used were obesity; Mellitus diabetes; diabesity; semaglutide; type 1 glucagon-like peptide analogue. The search engines corresponding to the Google Scholar, PubMed and SciElO databases were used. Different review, research and web pages were evaluated, which in general were published no more than 10 years ago, in Spanish, Portuguese or English and which dealt with the subject of study by title. Articles that did not address the relationship between diabetes and obesity, as well as treatment with glucagon-like peptide 1 analogues, were excluded. This allowed the consultation of 84 articles, 59 of them were referenced.
Conclusions:
The use of semaglutide, as a complement to a diet and physical activity appropriate to the needs of patients with diabesity, brought about several effects that favor better evolution of this health problem, by optimizing glycemic control, contributing to the loss of weight and the improvement of certain comorbidities, including cardiovascular health.
Palabras clave : obesity; mellitus diabetes; diabesity; semaglutide; glucagon-like peptide type 1 analog.